Scotiabank Maintains Sector Outperform on NewAmsterdam Pharma, Raises Price Target to $52
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Scotiabank analyst George Farmer maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform and raises the price target from $47 to $52.
Scotiabank analyst George Farmer maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform and raises the price target from $47 to $52.